633327-22-7

Basic information

• Product Name: 5-BROMO-2,3-DIFLUORO-BENZALDEHYDE
• Synonyms: 5-BROMO-2,3-DIFLUORO-BENZALDEHYDE
• CAS NO: 633327-22-7
• Molecular Formula: C₇H₃BrF₂O
• Molecular Weight: 220.9989264
• Mol File: 633327-22-7.mol

Chemical Properties

• Boiling Point: 230.0±35.0 °C(Predicted)
• Appearance: /
• Density: 1.758±0.06 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• CAS DataBase Reference: 5-BROMO-2,3-DIFLUORO-BENZALDEHYDE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-BROMO-2,3-DIFLUORO-BENZALDEHYDE(633327-22-7)
• EPA Substance Registry System: 5-BROMO-2,3-DIFLUORO-BENZALDEHYDE(633327-22-7)

Safety Data

• Hazardous Substances Data: 633327-22-7(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
5-Bromo-2,3-Difluoro-Benzaldehyde is used as a chemical intermediate for the synthesis of various complex organic molecules. Its unique structure with halogenated elements allows for versatile reactions and the creation of a wide range of compounds.
Used in Pharmaceutical Manufacturing:
In the pharmaceutical industry, 5-Bromo-2,3-Difluoro-Benzaldehyde is used as a building block in the development of new drugs. Its reactivity and structural properties make it a valuable component in the synthesis of potential therapeutic agents.
Used in Chemical Research:
5-Bromo-2,3-Difluoro-Benzaldehyde is also utilized in academic and industrial research settings to study the properties and reactions of halogenated aromatic compounds. This helps in understanding the behavior of such compounds and their potential applications in various fields.

Upstream product

• 348-61-8 1-bromo-3,4-difluorobenzene 
• 68-12-2 N,N-dimethyl-formamide 
• 2646-91-5 2,3-difluorobenzaldehyde 
• 633327-21-6 5-bromo-2,3-difluoro-4-trimethylsilanylbenzaldehyde 

Downstream Products

• 887585-71-9 (5-bromo-2,3-difluorophenyl)methanol 
• 1105665-42-6 5-bromo-2,3-difluorobenzonitrile 
• 1365889-33-3 (E)-5-bromo-2,3-difluorobenzaldehyde O-methyl oxime 
• 445303-65-1 2-[3-(difluoromethyl)-4-fluoro-phenyl]-4,4,5,5-tetramethyl-1,3,2-dioxaborolane 
• 1805422-92-7 5-bromo-1-(difluoromethyl)-2,3-difluorobenzene 
• 633327-24-9 7-fluoro-1H-indazole-5-carbonitrile 
• 1445796-37-1 C₁₂H₁₃F₂NO₃ 
• 1445796-44-0 C₇H₆F₃N 
• 1445796-43-9 C₁₂H₁₄F₃NO₂ 
• 1445796-42-8 C₁₂H₁₅F₂NO₃ 
• 1445796-41-7 C₁₄H₁₇F₂NO₄ 
• 1445796-40-6 C₉H₇BrF₂O₂ 
• 1445796-39-3 C₇H₅F₄N 
• 1445796-38-2 C₁₂H₁₃F₄NO₂ 

Relevant articles and documents

Liquid crystal compound containing dibenzothipheno oxygen-containing heterocycles and application thereof featuring high dielectric constant, high clearing point, high refractive index, high K value, etc., and suitable for displays used in VA, ECB, PALC, FFS or IPS mode

The present invention belongs to the field of liquid crystal compound materials, and relates to a liquid crystal compound containing dibenzothieno oxygen-containing heterocycles and its applications. The chemical structural formula is shown as the following formula I. The liquid crystal compound provided by the present invention and the liquid crystal composition containing the compound have the properties of high dielectric constant, high clearing point, high refractive index, high K value, etc., and is suitable for displays used in VA, ECB, PALC, FFS or IPS mode.

POTENT HUMAN NEURONAL NITRIC OXIDE SYNTHASE INHIBITORS

Disclosed are 2-aminopyridine derivative compounds for use as inhibitors of nitric oxide synthase (NOS). In particular, the field of the invention relates to 2-aminopyridine derivative compounds for use as inhibitors of neuronal nitric oxide synthase (nNOS), which are formulated as pharmaceutical compositions for treating diseases and disorders associated with nNOS such as Alzheimer's, Parkinson's, and Huntington's diseases, and amytrophic lateral sclerosis, cerebral palsy, stroke/ischemic brain damage, and migraine headaches.

Cyclic aminopyrimidine derivative and activity and application thereof for inhibiting kinase (by machine translation)

The cyclic aminopyrimidine derivative has the structure of a general formula (I), a pharmaceutically acceptable salt, ester or solvate thereof, can inhibit the activity of kinases, is a plurality of kinase inhibitors, can be widely applied to treatment of cancers, and has a huge clinical application prospect. General Formula (I). (by machine translation)

Compounds and their use in treatment on hepatitis B

The invention provides compounds, a pharmaceutical composition containing the compounds and an application of the compounds. The compound is a compound shown in a formula (I) or a stereoisomer, a tautomer, nitric oxide, hydrate, solvate, metabolite, pharmaceutically acceptable salt or prodrug of the compound shown in the formula (I). The compound provided by the invention can interfere with the shell assembly process of hepatitis B virus, thereby inhibiting hepatitis B virus replication. Moreover, the compound has good absorption, relatively high biological activity and availability and low toxicity, particularly has relatively strong stability in vivo, is not easy to decompose and has long drug effect time, so that an effect of treating hepatitis B is achieved and the compound has a goodapplication prospect.

Optimization of Blood-Brain Barrier Permeability with Potent and Selective Human Neuronal Nitric Oxide Synthase Inhibitors Having a 2-Aminopyridine Scaffold

Effective delivery of therapeutic drugs into the human brain is one of the most challenging tasks in central nervous system drug development because of the blood-brain barrier (BBB). To overcome the BBB, both passive permeability and efflux transporter liability of a compound must be addressed. Herein, we report our optimization related to BBB penetration of neuronal nitric oxide synthase (nNOS) inhibitors toward the development of new drugs for neurodegenerative diseases. Various approaches, including enhancing lipophilicity and rigidity of new inhibitors and modulating the pKa of amino groups, have been employed. In addition to determining inhibitor potency and selectivity, crystal structures of most newly designed compounds complexed to various nitric oxide synthase isoforms have been determined. We have discovered a new analogue (21), which exhibits not only excellent potency (Ki 30 nM) in nNOS inhibition but also a significantly low P-glycoprotein and breast-cancer-resistant protein substrate liability as indicated by an efflux ratio of 0.8 in the Caco-2 bidirectional assay.

AMINO PYRIMIDINE COMPOUND FOR INHIBITING PROTEIN TYROSINE KINASE ACTIVITY

An amino pyrimidine compound for inhibiting protein tyrosine kinase activity, a pharmaceutical composition thereof, preparation therefor, and an application thereof. Specifically, an amino pyrimidine compound represented by formula (I), R1, R2, L, Y, R6, W, A, m, and n being defined in the specification, and a pharmaceutically acceptable salt, a stereoisomer, a solvent compound, a hydrate, a polymorphism, a prodrug, or an isotope variant thereof. The compound can be used for treating and/or preventing protein tyrosine kinase-related diseases such as cell proliferative diseases, cancers, and immune diseases.

SUBSTITUTED 2-HYDROGEN-PYRAZOLE DERIVATIVE SERVING AS ANTICANCER DRUG

Disclosed is a substituted 2H-pyrazole derivative serving as a selective CDK4/6 inhibitor. Specifically, disclosed is a compound of formula (I) or a pharmaceutically acceptable salt thereof which serves as a selective CDK4/6 inhibitor.

Amino pyrimidine compound and preparation method and application thereof

The invention relates to an amino pyrimidine compound and a preparation method and application thereof. The amino pyrimidine compound has a structure as shown in a formula I. The formula is shown in the description. The compound is an inhibitor of an epidermal growth factor receptor (EGFR) kinase. The invention further relates to a medicine composition comprising the compound, a preparation methodand application thereof in preparation of anti-tumor medicines.

3-(1H-PYRROLO[2,3-B]PYRIDIN-2-YL)-1H-INDAZOLES AND THERAPEUTIC USES THEREOF

Indazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an indazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

3-(1H-PYRROLO[2,3-C]PYRIDIN-2-YL)-1H-INDAZOLES AND THERAPEUTIC USES THEREOF

Indazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an indazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.